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https://doi.org/10.1016/j.stemcr.2019.07.005SUMMARYSubversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resis-
tant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia (AML). Using a conditional mouse model where zinc-finger
TF Gata2 was deleted specifically in hematopoietic cells, we show that knockout of Gata2 leads to rapid and complete cell-autonomous
loss of adult hematopoietic stem cells. By using short hairpin RNAi to target GATA2, we also identify a requirement for GATA2 in human
HSPCs. In Meis1a/Hoxa9-driven AML, deletion of Gata2 impedes maintenance and self-renewal of LSCs. Ablation of Gata2 enforces an
LSC-specific program of enhanced apoptosis, exemplified by attenuation of anti-apoptotic factor BCL2, and re-instigation of myeloid
differentiation––which is characteristically blocked in AML. Thus, GATA2 acts as a critical regulator of normal and leukemic stem cells
and mediates transcriptional networks that may be exploited therapeutically to target key facets of LSC behavior in AML.INTRODUCTION
Hematopoiesis is contingent on a rare pool of self-renewing
hematopoietic stem cells (HSCs) and progenitors that are
regulated by a combination of a cell-extrinsic program,
imparted by the bone marrow (BM) niche in which they
reside, and a cell-autonomous program driven by transcrip-
tion factors (TFs), which regulate gene expression (Beck
et al., 2013). Through loss-of-function genetic mouse
models, the differentiation-stage requirement for specific
TFs in myeloid and lymphoid committed progenitors has
been characterized comprehensively (Orkin, 2000); yet,
with few exceptions (Hock et al., 2004; Kranc et al., 2009;
Pajerowski et al., 2010), the transcriptional program critical
to adult HSC survival remains unclear.
Perturbed TF activity in the form of TF chromosomal
translocations and loss- or gain-of-function genetic and
epigenetic mutations in TFs has been implicated in the
pathogenesis of hematologic malignancies, including
acute myeloid leukemia (AML). AML is driven by a subset
of leukemia cells––namely leukemic stem cells (LSCs) (Bon-
net andDick, 1997)––which are acknowledged to underpin
leukemic growth andmaintenance and, notably, are refrac-
tory to standard AML chemotherapeutics (Craddock et al.,
2013; Ishikawa et al., 2007; Saito et al., 2010). Like theirSte
This is an open access article under the Cnormal HSC counterparts, however, the requirement for
TFs in LSC function is poorly defined; thus a deeper under-
standing of transcriptional regulation in this setting will
afford insights toward specific targeting of LSCs, which
will be necessary for improving the clinical armamen-
tarium in AML.
Gata2, part of the zinc finger family of GATA family of
TFs (Nagai et al., 1994), has been identified as a critical regu-
lator of HSCs during ontogenesis of the hematopoietic sys-
tem (Tsai et al., 1994). Constitutive lack ofGata2 (Gata2/)
leads to embryonic fatality at embryonic day 10.5 (E10.5)
due to anemia (Tsai et al., 1994). Chimera experiments
demonstrated thatGata2/ embryonic stem cells were un-
able to contribute to the formation of myeloid and
lymphoid cells at the fetal liver (FL) developmental stage
and in adult mice, suggesting that Gata2 acts as a crucial
regulator of HSCs (Tsai et al., 1994). To formally assess
the requirement for Gata2 in HSCs during embryonic
development, using conditional knockout (KO) genetic
models, Gata2 has been deleted in hemogenic endothe-
lium cells, before the generation of HSCs using Vec-Cre
(de Pater et al., 2013; Lim et al., 2012), and immediately
following HSC formation using Vav-Cre (de Pater et al.,
2013). Through functional analysis of Gata2-deficient
cells from temporally restricted hematopoietic organsm Cell Reports j Vol. 13 j 1–16 j August 13, 2019 j ª 2019 The Authors. 1
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tings, Gata2 has been revealed as a pivotal regulator of
cell-autonomous HSC generation and, thereafter, for HSC
survival in the embryo. By analysis of haploinsufficient
Gata2+/ mice that express reduced Gata2, we and other
laboratories have examined the impact of Gata2 gene
dosage in adult hematopoiesis (Guo et al., 2013; Ling
et al., 2004; Rodrigues et al., 2005). BM from Gata2+/
mice displayed a reduction in abundance of immunophe-
notypically defined HSCs and in functionality during
transplantation assays (Guo et al., 2013; Rodrigues et al.,
2005). This was associated with decreased HSC prolifera-
tion, enhanced HSC quiescence and apoptosis, and
attendant downregulation of anti-apoptotic BCL-XL in
Gata2+/ mice (Ling et al., 2004; Rodrigues et al., 2005).
Gata2 haploinsufficiency also reduces granulocyte-macro-
phage progenitor (GMP) cell function while leaving other
myeloid committed progenitors intact (Rodrigues et al.,
2008). Conversely, forced expression of GATA2 in adult
HSCs has similarly implicated Gata2 as a critical level-
dependent regulator of adult HSC proliferation and differ-
entiation (Persons and Allay, 1999).
Emphasizing the biological and clinical imperative to
maintain normal GATA2 expression in adult hematopoi-
esis, deregulated GATA2 expression has been linked to
the pathogenesis of pre-leukemic myelodysplastic syn-
drome (MDS) and AML. In its capacity as a tumor sup-
pressor gene, loss of GATA2 expression in the context
of sporadic or hereditary GATA2 haploinsufficiency
mutations in coding or enhancer regions leads to immu-
nodeficiency syndromes that predispose to MDS/AML
when secondary mutations are attained (Hahn et al.,
2011; Hsu et al., 2013; Soukup et al., 2019). Far more
frequently, however, GATA2 overexpression has been
implicated as a harbinger of poor prognosis in adult
and pediatric AML, suggesting an oncogenic role for
GATA2 in AML (Luesink et al., 2012; Vicente et al.,
2012). Yet the requirement for GATA2 in AML cell fate
decisions, including in the AML-propagating LSC
compartment, remains poorly defined.
Using a genetic mouse model harboring conditional
alleles of Gata2 and an inducible Mx-1-Cre (Gata2fl/fl;Mx1-
Cre+), in which Gata2 expression can be deleted acutely
in hematopoietic cells on administration of the inter-
feron-a mimic, polyinosinic-polycytidylic acid (pIpC), we
investigated the hitherto unknown requirement for
Gata2 in adult HSCs and LSCs. We identify Gata2 as an
essential TF for adult HSC survival in BM and a unique he-
matopoietic TF required throughout HSC ontogeny. Using
a gene knockdown (KD) approach, we independently
demonstrate a conserved regulatory role for GATA2 in
human cord blood (CB) hematopoietic stem/progenitor
cells (HSPCs). Finally, we show that Gata2 regulates LSC2 Stem Cell Reports j Vol. 13 j 1–16 j August 13, 2019capacity to propagate AML through modulation of self-
renewal, apoptosis and myeloid differentiation fates.RESULTS
Gata2 Is Essential for Cell-Autonomous Adult HSC
Maintenance
We first assessed Gata2 expression in prospectively isolated
HSPCs from adult BM. Gata2 expression was highest in
HSCs, multipotent progenitors and hematopoietic progen-
itor cells-1/-2, reduced in committed myeloid progenitor
cells, and nearly extinguished in terminally differentiated
blood cell populations (Figure 1A).
Next, to assess the requirement for Gata2 in adult HSC
maintenance, we bred Gata2 harboring conditional alleles
of Gata2 (Gata2fl/fl mice) with Mx1-Cre to obtain a cohort
of Gata2fl/fl;Mx1-Cre+ or control mice (Gata2fl/fl;Mx1-Cre)
and administered pIpC on alternate days for 10 days to
achieve acute deletion of Gata2 (Gata2 KO). The impact
of Gata2 on hematopoiesis was assessed 14 days after the
last injection of pIpC (Figure 1B). Near complete loss of
GATA2 protein and Gata2 transcript was confirmed in
BM by western blot and qPCR analysis, respectively (Fig-
ures 1B and S1A). BM cellularity was significantly attenu-
ated in Gata2 KO mice in comparison with control mice
(Figure S1B). Immunophenotypic analysis revealed that,
while lymphoid lineages remained intact, a striking reduc-
tion of myeloid and erythroid cells was observed in the BM
and/or peripheral blood (PB) ofGata2 KOmice (Figures 1C,
S1C, and S1D). To identify the origin of myeloid and
erythroid cell loss in the context of Gata2 deficiency, we
assessed HSPCs from BM of Gata2 KO mice and found
a near complete loss of cells in the LSK compartment
(which contain HSCs and primitive progenitor cells) and
LK compartment (comprising committed myeloid and
erythroid progenitors) (Figure 1D). To investigate the
kinetics of HSC loss after Gata2 deletion, we assessed the
BM of Gata2 KO mice 5 days after the last pIpC dose (Fig-
ure 1B). Remarkably, we observed a near complete deple-
tion of myeloid cells and LSK and LK cells by day 5 (Figures
1E and 1F), indicating a rapid loss of HSCs immediately
following Gata2 deletion, consistent with a profound
HSC survival defect.
Mx1-Cre mediates gene deletion in hematopoietic cells,
extramedullary tissues, and in the BM niche (Ku¨hn et al.,
1995). To stringently evaluate whether Gata2 functions to
regulate HSC maintenance cell autonomously, we trans-
planted CD45.2+ BM cells from Gata2fl/fl;Mx1-Cre+ or con-
trol mice, which have not received pIpC, together with
unfractionated CD45.1+ BM cells in a competitive trans-
plant (Figure 1G). Similar engraftment was observed in
the PB of recipients transplanted with Gata2fl/fl;Mx1-Cre+
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weeks after transplantation, Gata2 deletion was induced
by pIpC administration, and efficient Gata2 deletion
in CD45.2+ BM cells of recipients transplanted with
Gata2fl/fl;Mx1-Cre+ cells was confirmed 14 days after the
last pIpC dose (Figure 1I).We observed a decrease in the fre-
quency of CD45.2+ Gata2 KO cells in BM, and to a lesser
extent in PB (Figure 1J). Further immunophenotypic anal-
ysis revealed a complete loss of myeloid cells in BM and PB
and a significant reduction of erythroid cells in BM (Figures
S1E and S1F). Strikingly, only CD45.1+ BM support cells
were able to contribute to HSPC maintenance; no
CD45.2+ Gata2 KO cells were detectable within the LSK
and LK compartments (Figures 1K and 1L). To test that
HSPC loss was not merely due to an attenuation of cell sur-
face markers that define HSCs, such as Sca-1 and c-kit, we
isolated vestigial Gata2 KO CD45.2+ BM cells from primary
recipients and transplanted them together with unfractio-
nated CD45.1+ competitor cells into secondary recipients
(Figure 1G). Four weeks after transplantation we found
no Gata2 KO cells in the BM or PB of the mice transplanted
with Gata2 KO BM cells (Figure 1M).
Having shown entire loss of the myeloid lineage while
lymphoid cells were preserved at 14 days after the last injec-
tion of pIpC in the BM of Gata2 KOmice, we next investi-
gated whether the lack of multi-lineage failure after Gata2
deletion was due to the relatively longer lifespan ofFigure 1. Gata2 Is Essential for Cell-Autonomous HSC Maintenan
(A) Gata2 expression in hematopoietic cells compared with Gata2
analyses: one-way ANOVA.
(B) Top: control and Gata2fl/fl;Mx1-Cre+ mice received six injections of p
injection. Bottom: GATA2 protein level in BM cells from control and G
(C and D) Fluorescence-activated cell sorting (FACS) plots of (C) mye
(HSPCs) from control and Gata2 KO mice at day 24 (n = 4).
(E and F) FACS plots showing (E) myeloid cells and (F) HSPCs from co
(G) CD45.2+ BM cells from untreated control or Gata2fl/fl;Mx1-Cre+ m
irradiated recipients. Six weeks later, mice received six doses of pIpC.
CD45.2+ BM cells transplanted into secondary irradiated recipients.
(H) Frequency of CD45.2+ cells in PB at week 6, before pIpC injection
(I) Representative gel showing genotyping of donor-derived CD45.2
fl, undeleted conditional allele.
(J) Frequency of CD45.2+ cells in BM and PB at day 24 (n = 4).
(K) FACS plots of CD45.1+ versus CD45.2+ chimerism in LSKs from tran
(L) Frequency of CD45.2+ cells in LSK and LK cells at day 24 (n = 4).
(M) Frequency of CD45.2+ cells in BM and PB 4 weeks after secondary
(N) CD45.2+ BM cells from untreated control and Gata2fl/fl;Mx1-Cre+
recipients. Six weeks later, mice received six doses of pIpC and were
(O) Frequency of CD45.2+ cells in PB after pIpC injection (n = 4). Erro
(P) FACS plots of CD45.1+ versus CD45.2+ chimerism in LSK cells at w
(Q) Representative gel showing genotyping of donor CD45.2+ fraction
allele; fl, undeleted conditional allele.
Data are mean ± SEM and n denotes number of mice used per genotype
unless otherwise indicated. *p < 0.05, **p < 0.01.
4 Stem Cell Reports j Vol. 13 j 1–16 j August 13, 2019lymphoid cells compared with myeloid cells. To test this
directly, we performed a long-term transplantation assay
to abolish Gata2 expression in a cell-autonomous manner
and monitored mice for 16 weeks to study the impact of
Gata2 deletion on long-term hematopoiesis (Figure 1N).
Analysis of PB revealed a continual decline in contribution
of Gata2 KO cells to blood lineages of recipient mice, with
less than 5% engraftment of Gata2 KO cells detectable at
16 weeks after Gata2 deletion, indicating a multi-lineage
defect in Gata2 KO cells (Figure 1O). In addition, BM anal-
ysis showed an absence of CD45.2+ Gata2 KO BM cells in
the LSK compartment at 16 weeks (Figure 1P). Full deletion
of the Gata2 gene was achieved in residual PB and BM
Gata2 KO cells at 16 weeks (Figure 1Q).
To eliminate the possibility ofGata2-dependent extrinsic
HSC regulation through the BMniche, we transplanted un-
fractionated CD45.1+ BM cells into lethally irradiated
CD45.2+Gata2fl/fl;Mx1-Cre+ or control mice. Six weeks after
transplantation, we administered pIpC to obtain Gata2-
deficient (Gata2 KO) or control BM niche recipient mice
and monitored the engraftment for up to 12 weeks (Fig-
ure S1G). The frequency of CD45.1+ cells in the PB of
Gata2 KO recipients remained comparable with those
transplanted in control mice (Figures S1H and S1I). In
concert, these data demonstrate that Gata2 is critically
required for cell-autonomous maintenance of HSCs and
multi-lineage hematopoiesis.ce
expression in HSCs (n = 3 independent experiments). Statistical
IpC on alternate days and were analyzed 15 or 24 days after the first
ata2 KO at day 24 after pIpC administration against GAPDH.
loid (Gr1+Mac1+) and (D) hematopoietic stem and progenitor cells
ntrol and Gata2 KO mice at day 15 (n = 3).
ice were transplanted with CD45.1+ wild-type (WT) BM cells into
Fourteen days after last pIpC dose (day 24) mice were analyzed and
(n = 4).
+ fraction BM from pIpC-treated recipient mice. D, excised allele;
splanted mice at day 24 (n = 4).
transplant (n = 4).
mice were transplanted with CD45.1+ WT BM cells into irradiated
analyzed for reconstitution for up to 16 weeks after last pIpC dose.
r bars depict SD. Statistical analyses: one-way ANOVA.
eek 16 (n = 3).
of the BM and PB of pIpC-treated recipients at week 16. D, excised
unless otherwise stated. Statistical analyses: Mann-Whitney U test
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Figure 2. GATA2 Is a Crucial Regulator of Human CB HSPC Function
(A) CB CD34+ cells were transduced with lentiviruses encoding a short hairpin against human GATA2 (or scramble control) and a GFP
reporter. GFP+ cells were FACS sorted and plated into CFC or LTC-IC.
(B) Relative GATA2 mRNA expression in CB CD34+ cells compared with GAPDH (n = 3 independent experiments).
(C) Colony-forming units (CFU) per 500 CD34+ GFP+ cells plated (n = 3 independent experiments). Statistical analyses: one-way ANOVA.
Data are mean ± SEM.
(D) Top: plot showing representative log-fraction of the limiting dilution model for the LTC-IC assay. The dotted lines give the 95%
confidence interval. Bottom: LTC-IC frequency calculated using ELDA software (n = 2 independent experiments).
*p < 0.05, ****p < 0.0001.
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Having shown the requirement for Gata2 in mouse adult
HSC function, we next sought to assess whether this role
was conserved in human HSPCs. Using a bicistronic
lentiviral vector system carrying a GFP reporter and short
hairpin (shRNA) targeted to GATA2 expression in CB
CD34+ HSPCs, we conducted functional analysis in
colony-forming cells (CFCs) and long-term culture-
initiating cell (LTC-IC) assays following GATA2 KD (Fig-
ure 2A). Reduction in GATA2 expression was confirmedin CB CD34+ cells transduced with two independent KD
constructs (Figure 2B). Overall CFC growth capacity and
lineage-specific CFCs (e.g., BFU-E) were markedly reduced
using either GATA2 KD constructs (Figure 2C). Limiting
dilution LTC-IC analysis revealed a marked reduction in
HSPC frequency using both KD constructs, in keeping
with the lack of multipotent progenitors (CFC-GEMM)
observed in CFC assays following GATA2 KD (Figures 2C
and 2D). Together these data demonstrate that GATA2
functions as a critical regulator of human HSPC function.Stem Cell Reports j Vol. 13 j 1–16 j August 13, 2019 5
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Self-Renewal in Meis1a/Hoxa9-Driven AML
To investigate the requirement of Gata2 in LSCs, we em-
ployed a tractable retroviral leukemogenic assay in which
leukemic transformation of murine C-KIT+ HSPCs is
driven by overexpression of Meis1a/Hoxa9, which is
observed in 40% of AML patients (Dorsam et al., 2004;
Lawrence et al., 1993). Meis1a/Hoxa9-transduced cells
were serially replated for three rounds in a CFC assay to
generate pre-LSCs, which, when injected into primary
lethally irradiatedmice, become LSCs and cause AML (Fig-
ure 3A). Given thatGata2fl/fl;Mx1-Cre+mice lack HSPCs by
day 15 after pIpC administration (Figure 1F), we instead
co-transduced HSPCs from non-induced Gata2fl/fl;Mx1-
Cre+ or control mice with retroviruses expressing Meis1a
and Hoxa9, and after three rounds of CFC we harvested
Meis1a/Hoxa9 pre-LSC and transplanted them into pri-
mary recipients together with unfractionated BM support
cells (Figure 3A). Wemonitored leukemia development by
episodic bleedings (Figure 3B) and inducedGata2 deletion
with pIpC once the percentage of leukemic cells in
the PB reached 20%–25%, a threshold for the diagnosis
of AML. Leukemia cells in the PB of recipients trans-
planted with Gata2fl/fl;Mx1-Cre+ pre-LSCs were dramati-
cally reduced at weeks 4 and 6 after pIpC treatment
(Figure 3C). Consistent with this, recipients of Gata2 KO
LSCs succumbed to AML with a significantly delayed
latency compared with recipients of control LSCs, indi-
cating that Gata2 deletion impairs LSC maintenance (Fig-
ure 3D). Notably, these results were obtained with 33%
recipients harboring Gata2 KO leukemic cells with com-
plete Gata2 deletion.Figure 3. Acute Deletion of Gata2 Impairs LSC Development and
(A) C-kit+ cells from control or Gata2fl/fl;Mx1-Cre+micewere transducedw
After CFC3, pre-LSCs (CD45.2+ c-kit+) were sorted and transplanted into
Three weeks later, mice were injected with pIpC. LSCs (CD45.2+ c-kit+)
(B) Frequency of leukemic (CD45.2+) cells in PB before pIpC (n = 6).
(C) Frequency of leukemic cells in PB at the indicated days after pIpC
(D) Kaplan-Meier survival curve of recipients transplanted with pre-L
(E) Kaplan-Meier survival curve of recipients transplanted with LSCs (
(F) Pre-LSCs (CD45.2+ c-kit+) from the two genotypes were sorted and t
unfractionated BM cells. Three weeks later, mice were injected with pI
of pIpC.
(G) Frequency of leukemic cells in PB before and after pIpC (n = 6–7)
(H) Representative images of reduced splenomegaly in Gata2 KO mic
(I) Spleen weight at day 7 (n = 6–7).
(J and K) Frequency of leukemic cells in (J) SP and in (K) BM at day
(L) Representative FACS plot of LSCs in BM.
(M) Frequency of LSCs (CD45.2+ c-kit+) in BM at day 7 (n = 6–7).
(N) Representative gel showing genotyping from donor-derived LSC fr
allele; fl, undeleted conditional allele.
Data are mean ± SEM and n denotes number of mice used per genotype
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.To investigate whether Gata2 deletion also compro-
mises LSC self-renewal, we prospectively isolated LSCs
from BM of mice exhibiting complete deletion of Gata2
or controls by fluorescence-activated cell sorting and
transplanted them into secondary recipients together
with unfractionated BM support cells (Figure 3A). Recipi-
ents transplanted with Gata2 KO LSCs developed AML
more slowly than recipients transplanted with control
LSCs (Figure 3E). Taken together, these data demonstrate
that Gata2 is required for LSC maintenance, self-renewal,
and leukemia propagation in a Meis1a/Hoxa9-driven AML
mouse model.
That recipients of Gata2 KO LSCs eventually succumb to
AMLdemonstrates that, in striking contrast to their normal
HSC counterparts (Figure 1), LSCs survive Gata2 loss, sug-
gesting differential requirements for Gata2 in subsets of
C-KIT+ HSPCs during transformation. The cell of origin
for Meis1a/Hoxa9-driven AML in C-KIT+ HSPCs is either
LSK or common myeloid progenitor (CMP) but not GMP
(Wang et al., 2010). We investigated which of these HSPC
subsets was dependent on Gata2 during transformation
in Meis1a/Hoxa9-driven AML. Meis1a/Hoxa9 LSK and
CMP-derived pre-LSCs from Gata2fl/fl or Gata2+/+ mice
were transduced with lentiviruses encoding Cre and iVenus
reporter. Transduced iVenus+ cells were serially plated in
CFC assays for three rounds, and were immunophenotypi-
cally assessed at each stage for expression of C-KIT+, as a
marker of LSCs, and GR1 and MAC1 myeloid differentia-
tion markers, which are blocked in AML development.
While LSC and MAC1 expression was similar between
genotypes in LSK and CMP compartments throughout
replating (Figures S2A–S2D), LSK cells from Gata2 KOSelf-Renewal
ith retroviruses expressingMeis1a/Hoxa9 andplated into CFC assays.
lethally irradiated recipients with CD45.1+ unfractionated BM cells.
from primary recipients were transplanted into secondary recipients.
injection (n = 6). Statistical analyses: one-way ANOVA.
SCs (n = 6). Statistical analyses: Mantel-Cox test.
n = 6–8). Statistical analyses: Mantel-Cox test.
ransplanted into lethally irradiated recipients together with CD45.1+
pC, and were analyzed or used for RNA-seq 7 days after the last dose
.
e.
7 (n = 6–7).
action of the BM of pIpC-treated recipient mice at day 7. D, excised
. Statistical analyses: Mann-Whitney U test unless otherwise stated.
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In contrast, a relative blockade in GR1 expression was
observed from Gata2 KO in Meis1a/Hoxa9-transformed
CMP at CFC3 (Figure S2F). These data suggest that HSC-
enriched LSKs mediate GATA2 regulation of transforma-
tion in Meis1/Hoxa9 AML, whereas CMPs regulate
transformation in this setting independently of GATA2.
Acute Deletion of Gata2 Promotes an LSC-Specific
Program of Apoptosis and Myeloid Differentiation
in Meis1a/Hoxa9-Driven AML
To examine the molecular signature governing LSC main-
tenance and self-renewal driven by GATA2, we performed
global gene expression analysis by RNA sequencing (RNA-
seq) of Gata2 KO and control LSCs. MEIS1a and HOXA9
expressing pre-LSCs (CD45.2+ c-kit+) were transplanted
into lethally irradiated recipientmice together with unfrac-
tionated CD45.1+ BM support cells (Figure 3F). When the
levels of AML in PB reached 25%, we administered pIpC
to delete Gata2 in LSCs and analyzed mice 7 days after
the last dose of pIpC (Figure 3F). The frequency of AML
cells in PB was comparable between both genotypes before
pIpC administration (Figure 3G), yet in mice harboring
Gata2 KO LSCs there was a 3.5-fold reduction in the PB at
7 days after administration of the last dose of pIpC (Fig-
ure 3G). Splenomegaly, a hallmark of AML, was markedly
reduced in recipients with Gata2 KO LSCs 7 days after the
last pIpC injection (Figures 3H and 3I). This corresponded
to a reduced population of engrafting AML cells in the
spleen ofGata2 KO LSC recipients (Figure 3J). Immunophe-
notypic analysis was also conducted on BM, which re-
vealed a decrease in bulk AML cells and a 3-fold reduction
in the abundance of LSC (CD45.2+ c-kit+) in recipients
harboring Gata2 KO LSCs (Figures 3K–3M). Full deletion
ofGata2was achieved inGata2 KO LSCs (Figure 3N). Using
pathway analysis of RNA-seq using the Gene Ontology
Consortiumand gene set enrichment analysis, we observed
differential upregulation of pathways modulating meta-
bolic processes and pathways that curtail cell proliferation
and downregulation of G-coupled receptor signaling,
oxidative phosphorylation, and C-MYC target genes in
Gata2 KO LSCs (Figures 4A and S3A). Furthermore, Gata2
KO LSCs exhibited dampening of lysosome signaling,
which targets AML LSCs (Sukhai et al., 2013), and theFigure 4. Transcriptional Signature of Gata2 KO LSCs Shows Dere
Gene expression analyses were performed in sorted control or Gata2 KO
genotype).
(A) Biological processes enriched in up- and downregulated genes in
using the Gene Ontology Consortium database. Data are shown as –lo
(B and C) Heat maps reflecting expression levels of (B) apoptotic genes
and myeloid and lymphoid differentiation-associated genes that are
LSCs. (D) GSEA plots showing apoptosis and stem cell differentiationnuclear factor kB signaling pathway, the activation of
which is associated with a pro-inflammatory environment
permissive for the development and maintenance of AML
(Figures S3A and S3B) (Wang et al., 2014; Zambetti et al.,
2016).
To identify GATA2 target genes specific to LSCs rather
than HSCs, we compared RNA-seq data from Gata2 KO
LSCs with GATA2 target genes identified from HSCs. As
genetic deletion of Gata2 entirely abolishes immunophe-
notypically defined HSCs (Figure 1), we instead conduct-
ed RNA-seq on HSCs from Gata2 haploinsufficient
mice bearing a single floxed allele deleted by Vav-iCre
(Gata2+/fl;Vav-iCre+) in vivo, where adult HSCs remain
isolatable but are reduced in abundance (de Pater et al.,
2013) (our unpublished observations). Using Ingenuity
Pathway Analysis of differentially expressed genes in
HSCs and LSCs, we found that several GATA2-mediated
biological pathways, including ERK/MAPK and inter-
leukin-4 signaling, were shared between HSCs and LSCs
(Figure S3C). Seventy genes were differentially expressed
inGata2+/fl;Vav-iCre+HSCs and 689 differentially expressed
inGata2 KO LSCs, yet amere 4 GATA2 target genes (Lphn2,
Mllt3, Gimap4, and Zhx2) were common to bothHSCs and
LSCs. Thus, the vast majority of GATA2 target genes identi-
fied here were exclusive to LSCs. In agreement with the
notion that lack ofGata2 engenders an anti-leukemic effect
in LSCs, established AML tumor suppressors or oncogenes
were up- or downregulated, respectively, in Gata2 KO LSCs
(Figure 4B). As expected, previously identified GATA2
target geneswere deregulated inGata2 KO LSCs (Figure 4C).
We observed gene signatures in Gata2 KO LSCs consistent
with re-activation of both lymphoid and erythroid differ-
entiation potential (e.g., Epo-R) (Figure 4C). Most notably,
Gata2 KO LSCs registered a robust pro-apoptotic and
myeloid cell differentiation gene signature (Figures 4A–
4D). These data suggest that ablation of Gata2 could alle-
viate the myeloid differentiation and apoptotic block in
AML LSCs––cell fates that are characteristic and indispens-
able for facilitating AML maintenance and propagation
(Ishikawa et al., 2007; Sykes et al., 2015).
Next, to directly assess whether apoptosis was
augmented in Gata2 KO LSCs, we conducted an annexin
V assay on Gata2 KO LSCs at 7 days after the last pIpC in-
jection (Figure 3F), which indeed confirmed an increasegulated Apoptotic and Myeloid Differentiation Pathways
LSCs using the same experimental design as Figure 3F (n = 4 mice per
Gata2 KO LSCs compared with control LSCs. Analyses was performed
g10 (p value), and the dotted orange line indicates p value = 0.05.
and regulators of AML leukemogenesis, and (C) Gata2 target genes,
significantly differentially expressed between control or Gata2 KO
signature gene sets.
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Figure 5. Deletion of Gata2 in LSCs Leads to an Increase in Apoptosis and Enhanced Myeloid Differentiation
Analyses were performed in control or Gata2 KO LSCs using the experimental design in Figure 3F.
(A) Frequency of annexin V+ cells in LSCs (n = 6–7).
(B) Representative histogram plot showing the levels of BCL2 protein in control and Gata2 KO LSCs.
(C) MFI of BCL2 in LSCs in relation to the MFI of isotype control (n = 6–7).
(D) Representative histogram plot showing the levels of Mac1 and Gr1 protein in leukemic cells. Red dotted line indicates the highest
expression of each marker.
(E) Gating strategy to distinguish AML blast cells with differentially expressed Gr1 and Mac1 levels: Gr1highMac1high, Gr1lowMac1high,
Gr1highMac1low, andGr1lowMac1low. Representative FACSplots showingan increase inGr1highMac1high population after deletionofGata2 in LSCs.
(F) Frequency of the indicated populations in BM of leukemic mice (n = 6–7). Statistical analyses: one-way ANOVA.
Data are mean ± SEM and n denotes number of mice used per genotype. Statistical analyses: Mann-Whitney U test unless otherwise
indicated. *p < 0.05, **p < 0.01.
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try, we measured protein levels of crucial apoptotic regula-
tors in Gata2 KO LSCs or control LSCs. Between Gata2 KO10 Stem Cell Reports j Vol. 13 j 1–16 j August 13, 2019LSCs and their LSC control counterparts, no changes were
discernible with respect to themean fluorescence intensity
(MFI) of P53, or the activation of the survival-promoting
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Given that BCL-XL regulates cell survival in the context of
GATA factor-dependent erythroid cell differentiation
(Gregory et al., 1999), we assessed BCL-XL expression in
Gata2 KO LSCs and Gata2 haploinsufficient HSCs from
both Mx1-Cre or Vav-iCre systems, but found that expres-
sion was unperturbed in all settings (Figures S3F, S3H,
and S3J). In stark contrast, a significant reduction in the
MFI of anti-apoptotic protein BCL2 was found only in
Gata2 KO LSCs (Figures 5B, 5C, S3G, and S3I). Thus, acute
deletion of Gata2 produces a rapid loss of LSCs, consistent
with perturbed cell survival and mediated partly by atten-
uation of BCL2 expression. Furthermore, GATA2-mediated
regulation of Bcl2 in LSCs represents a novel GATA-
dependent cell survival mechanism specific to LSCs rather
than HSCs.
Having identified an enhanced myeloid differentiation
gene signature in Gata2 KO LSCs, we next asked whether
this reflected GATA2-mediated alterations in myeloid
differentiation of AML blasts in vivo. Using immunophe-
notyping, we analyzed the differentiation status of total
BM from mice harboring Gata2 KO LSCs at 7 days after
the last pIpC injection (Figure 3F). A trend toward
increased GR1 or MAC1 expression was observed in
bulk AML cells derived from Gata2 KO LSCs (Figure 5D),
which mapped specifically to a significant increase in the
abundance of GR1highMAChigh myeloid cells (Figures 5E–
5F). Together with gene expression profiling data of
Gata2 KO LSCs, these data support the contention that
ablation of Gata2 in LSCs increases their differentiation
capacity in vivo, raising the possibility that targeting
the GATA2 differentiation affiliated transcriptional
network in LSCs could pave the way toward novel ther-
apeutics in AML.DISCUSSION
In this report, to explore the genetic requirement for Gata2
in adult hematopoiesis, we employed a conditional gene-
targeting approach using the Mx1-Cre system to specif-
ically delete Gata2 in hematopoietic cells from adult
mice. Consistent with data using ER-Cre-mediated deletion
of theGata2C-terminal zinc-finger domain (Li et al., 2016),
we demonstrate that acute genetic ablation of Gata2 leads
to a rapid and complete cell-autonomous loss of adult
HSCs and multi-lineage potential. Therefore, Gata2 joins
a select list of TFs that are indispensable for adult HSC
maintenance and survival (Hock et al., 2004; Kranc et al.,
2009; Pajerowski et al., 2010). Loss-of-function studies in
mice have identified various TFs required for distinct
temporal and developmental stages of hematopoiesis, as
typified by Runx1, which is required for HSC generationfrom hemogenic endothelium, but expendable for HSC
maintenance for the remainder of gestation and in adult
HSCs in the BM (Chen et al., 2009). Cited2, a reported
upstream regulator of Gata2 in hematopoiesis (Saito et al.,
2015), is a pivotal functional regulator of embryonic and
adult HSCs, yet genetic KO models also highlight key
stage-specific requirements during HSC development. For
example, conditional genetic KOofCited2 in adult hemato-
poiesis using Mx1-Cre demonstrated the requirement
for Cited2 in adult HSC survival via Ink4a/Arf and p53
(Kranc et al., 2009). In contrast, conventional germline
deletion of Cited2 produced isolatable HSCs at the FL stage,
althoughCited2/HSCswere impaired both in abundance
and functionality (Chen et al., 2007). Here, in concert with
data from de Pater et al. (2013), we importantly define
Gata2 as a unique TF that is necessary throughout
HSC ontogenesis––from cell-autonomous HSC generation
(using the Vec-Cre system) and HSC survival (using the
Vav-Cremodel) in the nascent blood system of the embryo
to adult HSC maintenance in BM. Evi1, another upstream
regulator of Gata2 in hematopoiesis, mirrors the require-
ment of Gata2 for HSC survival during development and
in the adult (Goyama et al., 2008; Sato et al., 2008; Yuasa
et al., 2005), although the explicit requirement for Evi1
in HSC generation from hemogenic endothelium in the
embryo remains untested and merits further investigation.
Using a lentiviral-based shRNAKDapproach,we extended
this study to examine the currently ill-defined requirement
for GATA2 in human HSPCs. Mirroring data from the Mx1-
Cre genetic mouse model, we observed that reducing
GATA2 expression in human CB CD34+ cells profoundly
altered HSPC function, as assessed by CFC and LTC-IC as-
says. Together, these data identify GATA2 as a regulator of
humanHSPCs, whichmaybear relevance for understanding
clinical GATA2 haploinsufficiency syndromes (Dickinson
et al., 2011; Hahn et al., 2011; Katsumura et al., 2018;
Soukup et al., 2019), in which the impact of GATA2 muta-
tions in HSPCs remains unclear. Identifying and character-
izing the genetic and epigenetic dependencies of specific
HSPC population(s) transformed by loss-of-function
GATA2 mutations and associated secondary mutations,
such as ASXL1, may offer mechanistic insights into the
wide range of complex pathologies and lineage-specific he-
matopoietic effects eventually leading to MDS/AML in
GATA2 haploinsufficiency syndromes.
Considering that accumulating evidence also suggests an
oncogenic function for GATA2 when it is overexpressed in
pediatric and adult AML (Luesink et al., 2012; Vicente
et al., 2012), we elected to interrogate the requirement for
Gata2 in LSCs by using an in vivo model of AML driven by
Meis1a/Hoxa9. Genetic deletion of Gata2 delayed in vivo
AML development by impairing the maintenance and self-
renewal of LSCs. Of note, gene expression patterns inStem Cell Reports j Vol. 13 j 1–16 j August 13, 2019 11
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setting of either Gata2 overexpression- or in Gata2 haploin-
sufficiency-relatedmodels (Katayama et al., 2017; Nandaku-
mar et al., 2015;Tippinget al., 2009). For example, lymphoid
differentiationblockade and c-Myc expression activationhas
been observed in the context of Gata2 overexpression
studies (Nandakumar et al., 2015; Tipping et al., 2009),
whereas Gata2 KO LSCs display a gene signature consistent
with reactivation of lymphoid differentiation and downre-
gulation of MYC target genes. Similarly, in leukemic cells
from Gata2 haploinsufficiency-related models (Katayama
et al., 2017), inwhichGata2acts as a tumor suppressor rather
than an oncogene, enrichment for oxidative phosphoryla-
tion and MYC target genes was observed, yet Gata2 KO
LSCs from Meis1a/Hoxa9 AML demonstrate reduction in
oxidative phosphorylation pathways. Thus, ablation of
Gata2 in LSCs pares down pro-oncogenic stimuli indicating
the potential for therapeutic intervention in AML.
To this end, deletion of Gata2 enhanced LSC apoptosis,
enriched for a pro-apoptotic and myeloid differentiation
signature in LSCs, and caused AML blast cell differentiation,
suggesting that characteristic biological traits of AML––
enhanced leukemic cell survival and a myeloid differentia-
tion block––can be ameliorated through inhibition of
GATA2 or targeting the GATA2 transcriptional network in
LSCs. Whether direct, transient inhibition of GATA2 in
LSCs is a possibility remains to be tested and is question-
able given the pivotal role identified here for Gata2 in
adult hematopoiesis and the known tumor-promoting role
of GATA2 in the context of haploinsufficiency. However, in
favor of this proposition, the proteasome inhibitor K7174,
which inhibits GATA2, has been found to be beneficial in
the treatment of multiple myeloma (Imagawa et al., 2003;
Kikuchi et al., 2013; Majik et al., 2012). We speculate that,
alternatively, it may be feasible to selectively target the
GATA2 transcriptional network in LSCs as GATA2 LSC target
genes identified here were specific to LSCs and not HSCs
(Iwasaki et al., 2015; Kikushige et al., 2010), which likely re-
flects differential transcriptional dependencies for Gata2 in
different cellular contexts (Rodrigues et al., 2005, 2008).
Our study suggests that the GATA2 pro-apoptotic tran-
scriptional network in LSCs, exemplified by Bcl2, may be
particularly susceptible to therapeutic targeting in AML,
while sparing normal HSPCs (Lagadinou et al., 2013;
Pollyea et al., 2018). Auspiciously, responses of BCL2 phar-
macological inhibitor, venetoclax, in combination with
standard AML chemotherapy agents, cytarabine, or hypo-
methylating agents, azacytidine and decitabine, are favor-
able compared with conventional induction therapy
(Konopleva and Letai, 2018). Furthermore, venetoclax
resistance in AMLmay be circumvented by using an inhib-
itor toward another BCL2 family member, MCL1 (Ramsey
et al., 2018).12 Stem Cell Reports j Vol. 13 j 1–16 j August 13, 2019The characteristicmyeloid differentiation block observed
in AML has been overcome successfully in a subtype of
AML, acute promyelocytic leukemia (APL), where a com-
bination of all-trans retinoic acid (ATRA) and arsenic
trioxide (ATO) has now become themainstay of treatment
for APL patients (Lallemand-Breitenbach and De The´,
2013). Evidence suggests that the combination of ATRA
and ATO cures APL by invoking myeloid differentiation
in LSCs and their progeny, AML blasts, thereby precipi-
tating LSC exhaustion (Werner et al., 2014; Zheng et al.,
2007). However, attempts to replicate induction of
myeloid differentiation in a similar manner across the ge-
netic and clinically diverse AML subtypes have met with
limited success (Sykes et al., 2016). We show here that
ablation of Gata2 in a non-APL AML model of LSCs over-
rides the myeloid differentiation block coupled to a deple-
tion of LSC survival and self-renewal ability, presumably
by promoting myeloid differentiation and apoptosis at
the expense of self-renewing LSCs. Because LSCs are cen-
tral to therapy resistance and relapse in AML (Craddock
et al., 2013; Ishikawa et al., 2007; Saito et al., 2010),
further investigation into how these LSC cell fates are
coordinated and transcriptionally regulated by GATA2
should lead to an understanding of whether combinato-
rial therapies are needed to effectively exhaust the func-
tionality of LSCs in AML.
Finally, the data presented here should also have direct
relevance to cancer stem cell (CSC) biology beyond AML.
Bearing in mind that LSCs serve as a paradigm for CSCs
in other tissues, this studymayhold significant importance
for understanding GATA2-mediated transcriptional pro-
gramming and developing clinical therapies against CSCs
in prostate and lung cancer, in which GATA2 is overex-
pressed and linked to aggressiveness (Kumar et al., 2012;
Vidal et al., 2015).EXPERIMENTAL PROCEDURES
Mice
Gene targeting of Gata2fl/fl mice has been described previously
(Charles et al., 2006), and mice were provided by Prof. Julian
Downward. Gata2fl/fl mice were bred with Mx1-Cre and Vav-iCre
mice (Vukovic et al., 2016). Gata2 conditional gene deletion in
theMx1-Cremodel was achieved by administration of six to eight
intraperitoneal injections of pIpC every other day (0.25 mg per
dose; GE Healthcare). All animals used for experiments were 8- to
12 weeks old in a C57BL/6 genetic background in accordance
with UK Home Office regulations.Meis1a/Hoxa9 Leukemic Transformation Assay
Meis1a-puro and Hoxa9-neo MSCV plasmids were used as
described previously (Vukovic et al., 2015). Further information
provided in Supplemental Experimental Procedures.
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C57BL/6 SJL (CD45.1), or C57BL/6 (CD45.2) for niche experiment,
adult recipient mice were irradiated with a split dose of 1,000 cGy
(137Cs source) 24 h before transplantation. Further information
provided in Supplemental Experimental Procedures.
Flow Cytometry
Samples were analyzed with a BD LSRFortessa and sorting experi-
ments were performed with a FACSAria Fusion (BD Biosciences).
Antibodies used are listed in Table S1. Further information
provided in Supplemental Experimental Procedures.
CB CD34+ HSPCs Isolation and Culture
Umbilical CB was obtained from full-term healthy pregnancies at
the Maternity Unit of the University Hospital of Wales, Cardiff,
following informed consent and approval from the South East
Wales Research Ethics Committee in accordance with the 1964
Declaration of Helsinki. Further detailed information provided in
Supplemental Experimental Procedures.
qRT-PCR and Western Blot
Further information provided in Supplemental Experimental
Procedures.
RNA-Seq and Bioinformatics
RNA-seq was performed on CD45.2+c-kit+ LSCs. Further informa-
tion provided in Supplemental Experimental Procedures.
Statistical Analyses
Further information provided in Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The accession number for the Gata2 LSC RNA-seq reported in this
paper is GEO: GSE133245. The accession number for the Gata2
HSC RNA-seq reported in this paper is GEO: GSE133248.
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